testosterone propionate

Small molecule

testosterone propionate is one of 8 small molecule programs targeting Atrophic Vaginitis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrophic VaginitisActive, not recruiting

Atrophic VaginitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Atrophic Vaginitis

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Phase 3

7 2

Pitocin

Estradiol Valerate

1 4

Estriol

IITF Research Pharma, S.L.U.

Phase 3

2 5

Reference

RRespirent Pharmaceuticals Co Ltd.

Phase 3

1 6

Generic Ingenol Mebutate

AActavis Inc.

Phase 3

1 7

Premarin

Pfizer

Phase 1

1 8

testosterone propionate

UUniversity of Vermont

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrophic Vaginitis1 trial

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

Suspended·UUniversity of Vermont·Phase 1/2·NCT01122342·30 enrolled

Unspecified1 trial

Hormones and Decision Making

Completed·UUniversity of Texas at Austin·Phase 4·NCT04865562·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for testosterone propionate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — testosterone propionate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for testosterone propionate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Vermont company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of Vermont

testosterone propionate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrophic Vaginitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News